OVIDNot HalalF
Unlock full report, free
Ovid Therapeutics Inc.

OVID: Is Ovid Therapeutics Inc. Halal?

Ovid Therapeutics Inc.

NASDAQHealthcareUS

$2.40

Market Cap: 447.9M

Compliance Status

Not Halal

Screened on Sep 23, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is Ovid Therapeutics Inc. (OVID) halal? Not Halal. Based on AAOIFI screening, Ovid Therapeutics Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Quote this verdict

HalalScreener rates Ovid Therapeutics Inc. (OVID) Not Halal, 0/100, grade F under AAOIFI Standard 21, screened Sep 23, 2026. Source: https://halalscreener.app/en/stock/OVID

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

2.7% of 30.0% limit
PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Screened according to AAOIFI Standard 21

What this means for you

Most scholars advise not holding OVID

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

Get an email if OVID's halal status changes

We re-screen Ovid Therapeutics Inc. daily. If the verdict moves, you hear about it the same day.

Free. One click sets it up, and you can unsubscribe any time.

About Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.

Sector: Healthcare · Industry: Biotechnology

Why this does not pass

  • Income from prohibited sources is over the 5% limit.

Screened under AAOIFI Standard 21. The exact figure behind this is part of Pro; the failing check and its limit are always free.

Shariah Compliance Status

AAOIFI Standard 21Updated Sep 23, 2026

See which ratio caused the failure.

See the exact debt ratio, interest income %, and prohibited revenue that caused the failure. Know before you sell or hold.

Free for 7 days. Cancel anytime.

AI Compliance Insight

PRO

Institutional-grade Shariah analysis

See why OVID is rated Not Halal with institutional-grade analysis

PRO DETAIL

The verdict above is final and free.

Pro members can verify every number behind it: interest-bearing deposits, prohibited income breakdown, and the full AAOIFI math.

Screened according to AAOIFI Standard 21

Compliance History

  1. Not Halalnow

    since Sep 2026

  2. Halal

    until the change above

  3. Under Review

    until the change above

  4. Not Halal

    until the change above

Tracked since Aug 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR
Free · No credit card required

Track OVID and 8,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

8,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Ovid Therapeutics Inc. (OVID) halal to invest in?
Ovid Therapeutics Inc. (OVID) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Ovid Therapeutics Inc. get a F compliance rating?
Ovid Therapeutics Inc. (OVID) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 2.7% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Ovid Therapeutics Inc.'s Shariah verdict?
Ovid Therapeutics Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Ovid Therapeutics Inc. re-screened for Shariah compliance?
Ovid Therapeutics Inc. (OVID) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Sep 23, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.